A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial

Tomomi Kamba,Toshiyuki Kamoto,Shinichiro Maruo,Takashi Kikuchi,Yosuke Shimizu,Shunichi Namiki,Kiyohide Fujimoto,Hiroaki Kawanishi,Fuminori Sato,Shintaro Narita,Takefumi Satoh,Hideo Saito,Mikio Sugimoto,Jun Teishima,Naoya Masumori,Shin Egawa,Hideki Sakai,Yusaku Okada,Toshiro Terachi,Osamu Ogawa

A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial

2017

Objective To examine the antitumor activity of zoledronic acid (ZA) combined with androgen deprivation therapy (ADT) for men with treatment-naive prostate cancer and bone metastasis.

Keywords:

Bone metastasis
Randomized controlled trial
Androgen
Bone disease
General surgery
Prostate cancer
Androgen deprivation therapy
Cancer research
Endocrinology
Zoledronic acid
Internal medicine
Medicine
Blockade
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations